Weight Load PET (WELPET)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-01

Study Completion Date

2024-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity related ailments, such as cardiovascular diseases (CVD) and metabolic disorders are major causes of death in the world. This trial may result in improved understanding of the causes of obesity and obesity-related disorders. Published data show that if a weight is carried by a rodent, this animal will lose body weight and gain an improved glucose control. Recently published data further show comparable results in humans when carrying an additional weight.

The investigators aim to confirm and further investigate these findings in humans. The investigators plan to let obese participants carry weight vests and monitor their change in glucose uptake in different tissues. This to further examine the effects increased axial loading has on glucose metabolism in different parts of the body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anti-obesity Treatment by Loading in Adult Subjects

NCT04697238

Obesity

COMPLETED NA

Effect of Different Weight Vests on Body Weight in Obese Individuals

NCT03672903

Obesity

COMPLETED PHASE1/PHASE2

Daily Self-Weighing for Obesity Management in Primary Care

NCT04044794

Overweight and Obesity

ACTIVE_NOT_RECRUITING NA

The Healthy Weight for Life Program

NCT01470222

Overweight Obesity Compliance Behavior

COMPLETED NA

Research Study of Nutritional Methods to Reduce Body Fat Percentages in Overweight and Obese Populations

NCT00487344

Obesity

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

STUDY OBJECTIVES AND ENDPOINTS

Primary objective

1. Determine if standing with a heavy weight vest (high load, i.e. 11 percent of body weight) for 3 hours increase glucose uptake in bone more than sitting (no load) for 3 hours.

Secondary objectives
2. Determine if standing with a heavy weight vest (high load, i.e. 11 percent of body weight) for 3 hours increase glucose uptake in fat tissue more than sitting (no load) for 3 hours.
3. Determine if standing with a heavy weight vest (high load, i.e. 11 percent of body weight) for 3 hours increase glucose uptake in muscle more than sitting (no load) for 3 hours.

STUDY DESIGN AND PROCEDURES

Overall study design and procedure protocol

This is an interventional, single center, imaging study with a within-subjects design. The aim is to investigate how increased loading affects the glucose uptake in the weight bearing bones measured with whole-body Positron Emission Tomography (PET)/Computed Tomography (CT) imaging together with the Fluorine-18 labeled glucose analog, 2-deoxy-2-\[18F\]-fluoro-D-glucose (18F-FDG). Glucose uptake in muscle and fat tissues will also be evaluated. All participants will test 2 different conditions with measurements of bone glucose uptake after:

1. No load - Participant in sitting position.
2. High load - Standing with a heavy weight vest consisting of 11 percent of the participants body weight.

Participants will receive loading for 3 hours before measurement with PET/CT imaging. Weight of weight vest are based on participants' body weight at the high load visit. Participants will continue with their normal lifestyle during the whole study. There will be a total of three study visits. Study visits will be on 3 separate days within approximately 3 weeks with a minimum of 2 days between each visit. Visits after screening will occur in a randomised order for all participants. All participants will undergo both study treatments and measurements will be compared within each participant from high load and no load visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

All participants will receive both treatments: (1) High load and (2) No load. This at to separate study visits.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High Load

Participants will be standing with a heavy weight vest (11 percent of body weight).

Group Type ACTIVE_COMPARATOR

Weight vest

Intervention Type DEVICE

A vest weighing up to a maximum of 15 kg.

No Load

Participants will be sitting.

Group Type PLACEBO_COMPARATOR

Wheelchair

Intervention Type DEVICE

Wheelchair in which participants will be sitting to reduce loading on lower extremities.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Weight vest

A vest weighing up to a maximum of 15 kg.

Intervention Type DEVICE

Wheelchair

Wheelchair in which participants will be sitting to reduce loading on lower extremities.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent to participate in the study.
2. Consent out of free will.
3. 18-65 years of age.
4. Maximum body weight of 115 kg.
5. Obesity as defined by a BMI \>30 and ≤35 kg/m2. Fat mass \>25 percent of total body weight.
6. Willingness to comply with the study protocol.
7. Confirmation of adequate function of major organs and systems as judged by investigator
8. Normal or clinically non-significant screening of blood samples:

1. Hemoglobin (Hb), White Blood Cell Count (WBC), thrombocyte count, sodium (Na), potassium (K), chloride (Cl), calcium (Ca), creatinine, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), glycated hemoglobin (HbA1c), fasting blood glucose, C-reactive protein (CRP), free thyroxine (fT4), thyroid stimulating hormone (TSH), Triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL).
2. Normal or clinically non-significant aberrations of screening blood samples are defined as:

i. Normal: Values within the reference interval supplied by the Turku University Hospital lab.

ii. Clinically non-significant aberration: as judged by investigator (Clinical significance judged by investigator)

Exclusion Criteria

1. Chronic disease that could interfere with the participation in the study as judged by the investigator such as neurological, renal, hepatic, endocrine, cardiovascular, pulmonary, hematological, or gastrointestinal disorders.
2. Diagnosed diabetes.
3. Chronic pain such as pain that is constant and impairs quality of life as judged by the investigator; for example: significant back, hip or knee pain.
4. Regular consumption of medications or natural supplements that affect weight, inhibit physical activity or increase the risk of adverse effects as judged by the investigator. The following drugs will not be accepted:

a. β-blockers, Glucagon-Like Peptide 1 (GLP-1)-agonists, Dipeptidyl Peptidase-IV (DPP-IV)-inhibitors, Sodium-glucose Cotransporter-2 (SGLT2)-inhibitors, sulfonylureas, insulin, orlistat, anti-obesity drugs, antidepressants, bisphosphonates, β2-agonists, intra articular or parenteral corticosteroids, diuretics, benzodiazepines, or central nervous system stimulating drugs such as methylphenidate or dextroamphetamine.
5. Gastric by-pass surgery or equivalent metabolic surgery in the gastrointestinal tract.
6. Reduced mobility as judged by the investigator.
7. Use of any illegal drugs according to local regulations, use of tobacco or nicotine products (e.g. cigarettes or snuff) or consuming excessive amounts of alcohol.

a. Excessive amounts of alcohol defined as:

i. Consumption of more than 9 glasses of wine for women, 14 glasses of wine for men (15 cl/glass 11 percent alcohol) or equivalent as judged by the investigator during an ordinary week will not be accepted.
8. Change in body weight of ≥5 kg during the last 3 months.
9. Drastic change in lifestyle during the last 3 months including a significant change in physical activity or dietary habits as judged by the investigator.
10. Apparent risk of not being able to comply with the study protocol for any reason as judged by the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes